UnknownNot Applicable

Protective Effects of Edaravone Dexborneol

China80 participantsStarted 2021-04-01

Plain-language summary

The patients of acute ischemic stroke were divided into two groups, edaravone dexborneol treatment group and edaravone treatment group. The purpose of this study was to observe the changes of imaging and the improvement of NIHSS and mRS in different groups.

Who can participate

Age range50 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Aged from 50 to 80 years old;
✓. Patients diagnosed as acute ischemic stroke according to Chinese guidelines for the diagnosis and treatment of acute ischemic stroke 2018 and who met the requirements of middle cerebral artery blood supply area infarction (except deep perforator disease) without treatment;
✓. Brain MR showed that the low perfusion area of ASL was at least 20% larger than that of DWI core infarct area, and the contralateral mirror brain tissue was basically normal;
✓. NIHSS score was between 4 to 24;
✓. Patient or their legal representatives were willing to sign the informed consent form.

Exclusion criteria

✕. Serious mental abnormality, complicated with heart, lung, liver, renal insufficiency or malignant tumor and other serious diseases;
✕. Combined with cerebral vascular malformation or cerebral hemorrhage;
✕. Pregnant or lactating women;
✕. Allergic to edaravone or dexborneol;
✕. There are interactions between the drugs being taken by patients and the study drug or affect the clinical trial parameters.

What they're measuring

image changes in different groups

Timeframe: 7 days

Trial details

NCT IDNCT05024526

SponsorLili Cao

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-12-31

Contact for this trial

Yu-Qing Fang, MD

+8618866883808 perfectin2000@163.com

View on ClinicalTrials.gov More Acute Ischemic Stroke trials